Rodman & Renshaw Reiterates Neoprobe Market Outperform, $7 PT

Rodman & Renshaw reiterated its Neoprobe

Outperform rating and $7 price target in a research report published today. In the report, Rodman & Renshaw states, "The licensing of AZD4694 highlights management's ability to execute on milestones set forth. Management continues to actively drive shareholder value by promoting the development and commercialization of Lymphoseek, and by moving a humanized RIGScan towards clinical development. Given the highly robust Phase 3 data package for Lymphoseek, we believe that Lymphoseek will garner FDA approval. Taken together, we believe Neoprobe represents an undervalued opportunity with multiple near-term drivers poised to create shareholder value." Shares of Neoprobe were trading at $2.50 at the time of posting, up 2.46% from Monday's market close.